Has Mohammad Saleh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $18,765 in general payments to Mohammad Saleh, MD across 1,130 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mohammad Saleh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mohammad Saleh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mohammad Saleh, MD

Endocrinology, Diabetes & Metabolism · Dearborn, MINPI 1639195456

Payments from drug & device makers

$18,765in general payments, 2019–2025

Across 1,130 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$3K
Novo Nordisk$3K
Amgen$2K
Corcept Therapeutics$1K
AstraZeneca$976
Xeris Pharmaceuticals, Inc.$837
plus $8K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	181	$3,074
Novo Nordisk	223	$2,608
Amgen(2 entities)	102	$1,893
Corcept Therapeutics	63	$1,340
AstraZeneca(2 entities)	69	$976
Xeris Pharmaceuticals, Inc.	53	$837
Antares Pharma, Inc.	42	$764
Sanofi-aventis U.S. LLC	47	$750
Amarin Pharma, Inc.	29	$485
Merck	35	$438
Dexcom, Inc.	21	$410
Amneal Pharmaceuticals LLC	20	$371
Tandem Diabetes Care, Inc.	14	$293
Currax Pharmaceuticals LLC	19	$277
Abbott	14	$276
Cequr Corporation	4	$244
Lifescan, Inc.	13	$215
Medtronic(2 entities)	5	$211
Rhythm Pharmaceuticals, Inc.	11	$209
BD	14	$204
AbbVie	9	$170
Recordati_rare_diseases_inc.	6	$169
Verity Pharmaceuticals Inc.	8	$158
Novartis	9	$157
Bayer	8	$146
Insulet Corporation	8	$141
Ascendis Pharma Endocrinology Inc	6	$141
Nevro Corp.	5	$136
Ipsen Biopharmaceuticals, Inc	5	$108
Madrigal Pharmaceuticals	3	$97
Braeburn Inc.	6	$96
Johnson & Johnson	6	$95
Zealand Pharma US, Inc.	5	$90
Ultragenyx Pharmaceutical Inc.	6	$89
Shire North American Group Inc	6	$85
Takeda Pharmaceuticals U.S.A., Inc.	3	$85
Mannkind Corporation	4	$79
Tolmar, Inc.	4	$71
Neurocrine Biosciences, Inc.	2	$67
IBSA Pharma Inc.	4	$60
Pfizer	3	$53
Halozyme Inc	2	$52
Embecta Corp.	3	$52
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	4	$50
Amphastar Pharmaceuticals, Inc.	2	$40
EUSA Pharma (US) LLC	2	$38
Acerus Pharmaceuticals Corporation	2	$36
Chiesi USA, Inc.	2	$34
Averitas Pharma Inc.	2	$33
Vivus LLC	2	$32
Eton Pharmaceuticals, Inc.	1	$26
Nalpropion Pharmaceuticals LLC	2	$25
Boehringer Ingelheim	1	$20
Kyowa Kirin, Inc.	1	$20
Valeritas, Inc.	1	$19
Gilead	1	$18
Lexicon Pharmaceuticals, Inc.	1	$18
Lundbeck LLC	1	$18
Redhill Biopharma Inc.	1	$17
Radius Health, Inc.	1	$17

How this compares

$18,765 in reported general payments places this provider in the 80th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan →

Medicare billing

Part B allowed, 2024

$275,342

Medicare patients

802

Services billed

3,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Dearborn

Opada AlzohailiDearborn$152K
Ali AchiraDearborn$9K
Tobias ElseAnn Arbor$3.5M
Elif OralAnn Arbor$2.9M
Jamal HammoudFlint$2.6M
Lowell SchmeltzFarmington Hills$2.3M
George GrunbergerBloomfield Hills$1.9M
Richard AuchusAnn Arbor$1.3M
Ariel BarkanAnn Arbor$553K
Gary EdelsonFarmington Hills$503K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →